Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Oct 17, 2011
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female Chinese subjects, ages ≥18 at screening
- • Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia (PHN). Subjects must have pain present for ﹥3 months after healing of the acute herpes zoster skin rash
- • At screening (V1), subjects must have a score ≥40mm on the 100-mm visual analog scale (VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)
- • At randomization (V2), subjects must have a score ≥40mm on the 100-mm visual analog scale (VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)
- • At randomization (V2), subjects must have completed at least 5 daily pain diaries (DPRS, see Appendix 2) and have an average daily pain score ≥4 over the past 7 days
- Exclusion Criteria:
- • Subjects who demonstrate a high response to placebo, with 30% decrease on the Pain Visual Analog Scale (VAS) at randomization as compared to screening
- • Subjects who have a high variability in pain scores during the 1 week screening period, with any difference between two scores ﹥3
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Jinan, Shandong, China
Guangzhou, , China
Shenzhen, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, , China
Shanghai, , China
Wuhan, Hubei, China
Wuhan, Hubei, China
Nanjing, Jiangsu, China
Suzhou, Jiangsu, China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Beijing, , China
Beijing, , China
Beijing, , China
Chengdu/Wuhou D, , China
Chongqing, , China
Shang Hai, , China
Shang Hai, , China
Shanghai, , China
Tianjin, , China
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials